View Future GrowthGivaudan 과거 순이익 실적과거 기준 점검 3/6Givaudan은 연평균 8.3%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 3% 증가했습니다. 매출은 연평균 3.2%의 비율로 증가했습니다. Givaudan의 자기자본이익률은 23.4%이고 순이익률은 14.3%입니다.핵심 정보8.34%순이익 성장률8.32%주당순이익(EPS) 성장률Chemicals 산업 성장률4.35%매출 성장률3.18%자기자본이익률23.45%순이익률14.33%다음 순이익 업데이트23 Jul 2026최근 과거 실적 업데이트공시 • Apr 15Givaudan SA to Report Fiscal Year 2026 Results on Jan 27, 2027Givaudan SA announced that they will report fiscal year 2026 results on Jan 27, 2027Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF116 (vs CHF118 in FY 2024)Full year 2025 results: EPS: CHF116 (down from CHF118 in FY 2024). Revenue: CHF7.47b (flat on FY 2024). Net income: CHF1.07b (down 1.7% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.공시 • Nov 08Givaudan SA to Report First Half, 2026 Results on Jul 23, 2026Givaudan SA announced that they will report first half, 2026 results on Jul 23, 2026Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF64.18 (vs CHF63.76 in 1H 2024)First half 2025 results: EPS: CHF64.18 (up from CHF63.76 in 1H 2024). Revenue: CHF3.86b (up 3.4% from 1H 2024). Net income: CHF592.0m (flat on 1H 2024). Profit margin: 15% (in line with 1H 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.공시 • Apr 10Givaudan SA to Report Fiscal Year 2025 Results on Jan 29, 2026Givaudan SA announced that they will report fiscal year 2025 results on Jan 29, 2026Reported Earnings • Jan 25Full year 2024 earnings released: EPS: CHF118 (vs CHF96.81 in FY 2023)Full year 2024 results: EPS: CHF118 (up from CHF96.81 in FY 2023). Revenue: CHF7.41b (up 7.2% from FY 2023). Net income: CHF1.09b (up 22% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates공시 • May 22Givaudan SA, Annual General Meeting, Mar 24, 2027Givaudan SA, Annual General Meeting, Mar 24, 2027.공시 • Apr 15Givaudan SA to Report Fiscal Year 2026 Results on Jan 27, 2027Givaudan SA announced that they will report fiscal year 2026 results on Jan 27, 2027공시 • Apr 08Givaudan Active Beauty Showcases AI-Powered Ingredient Innovations With Haut.AI At In-Cosmetics GlobalGivaudan Active Beauty, the reference in high-precision beauty ingredients, has partnered with Haut.AI, to spotlight a new era of AI-driven ingredient innovation. At this year's in-cosmetics Global 2026 (April 14–16, Paris), Givaudan Active Beauty will be the first to showcase its latest active ingredients through immersive GenAI-powered activations that allow attendees to virtually "experience" their benefits firsthand via personalized, photorealistic simulations powered by Haut.AI's SkinGPT technology. As the beauty industry accelerates toward measurable efficacy, personalization, and clinically validated claims, artificial intelligence is becoming a critical bridge between laboratory science and visible consumer outcomes. In this spirit, Givaudan has selected Haut.AI's scientifically grounded skin analysis and SkinGPT simulation technologies to deliver an interactive, ingredient-focused experience at one of the industry's most influential global stages. Building on this collaboration, Givaudan Active Beauty's latest active ingredient will serve as the foundation for an interactive SkinGPT-powered virtual try-on experience at the Givaudan booth in Paris. By taking a selfie of their own face, attendees will be able to digitally "apply" the ingredient and visualize how it may influence visible skin parameters over time through a photorealistic simulation. Meanwhile they will be able to experience an AI Skin Expert analyzing their skin and delivering personalized recommendations of high precision beauty ingredients. Givaudan Active Beauty's latest breakthrough, PrimalHyal™ NeuroYouth targets the newly identified Neuro Skin Ageing pathway, supporting nerve fiber regeneration and neuronal function. By integrating AI-powered validation and immersive simulations at booth at in-cosmetics Global, the company will share this innovation in a way that allows both customers and consumers to truly experience it. Visitors to the Givaudan Active Beauty booth will be invited to engage with two AI-powered experiences: SkinGPT: At in-cosmetics Global 2026, Givaudan will unveil its latest active ingredient in an immersive experience. For the first time, attendees will be able to literally try on the formulation on their own skin through a live facial scan, instantly visualizing how it may transform visible skin parameters over time. AI Skin Expert: An on-site skin assessment providing participants with comprehensive skin insights and active ingredient recommendations aligned with their unique skin characteristics.Upcoming Dividend • Mar 16Upcoming dividend of CHF72.00 per shareEligible shareholders must have bought the stock before 23 March 2026. Payment date: 25 March 2026. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (4.1%).공시 • Feb 23Givaudan SA, Annual General Meeting, Mar 19, 2026Givaudan SA, Annual General Meeting, Mar 19, 2026, at 10:30 W. Europe Standard Time.Declared Dividend • Feb 01Dividend increased to CHF72.00Dividend of CHF72.00 is 2.9% higher than last year. Ex-date: 23rd March 2026 Payment date: 25th March 2026 Dividend yield will be 2.4%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (55% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF116 (vs CHF118 in FY 2024)Full year 2025 results: EPS: CHF116 (down from CHF118 in FY 2024). Revenue: CHF7.47b (flat on FY 2024). Net income: CHF1.07b (down 1.7% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.공시 • Jan 30Givaudan SA announces Annual dividend, payable on March 25, 2026Givaudan SA announced Annual dividend of CHF 72.0000 per share payable on March 25, 2026, ex-date on March 23, 2026 and record date on March 24, 2026.공시 • Nov 08Givaudan SA to Report First Half, 2026 Results on Jul 23, 2026Givaudan SA announced that they will report first half, 2026 results on Jul 23, 2026공시 • Aug 28Givaudan SA Announces CEO ChangesGivaudan SA announced that Christian Stammkoetter would succeed its Chief Executive Officer, Gilles Andrier, who will retire after 20 years at the helm of the company. Stammkoetter-- who is currently president of Asia, Middle East and Africa at the French food company Danone--would take over the role effective March 1. Andrier will be proposed for election as chairman at the 2026 annual general meeting as Calvin Grieder is set to step down from the board after 12 years.Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF64.18 (vs CHF63.76 in 1H 2024)First half 2025 results: EPS: CHF64.18 (up from CHF63.76 in 1H 2024). Revenue: CHF3.86b (up 3.4% from 1H 2024). Net income: CHF592.0m (flat on 1H 2024). Profit margin: 15% (in line with 1H 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.공시 • Apr 10Givaudan SA to Report Fiscal Year 2025 Results on Jan 29, 2026Givaudan SA announced that they will report fiscal year 2025 results on Jan 29, 2026Upcoming Dividend • Mar 17Upcoming dividend of CHF70.00 per shareEligible shareholders must have bought the stock before 24 March 2025. Payment date: 26 March 2025. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (4.2%).공시 • Feb 24Givaudan SA, Annual General Meeting, Mar 20, 2025Givaudan SA, Annual General Meeting, Mar 20, 2025, at 10:30 W. Europe Standard Time.Declared Dividend • Feb 17Dividend increased to CHF70.00Dividend of CHF70.00 is 2.9% higher than last year. Ex-date: 24th March 2025 Payment date: 26th March 2025 Dividend yield will be 1.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jan 25Full year 2024 earnings released: EPS: CHF118 (vs CHF96.81 in FY 2023)Full year 2024 results: EPS: CHF118 (up from CHF96.81 in FY 2023). Revenue: CHF7.41b (up 7.2% from FY 2023). Net income: CHF1.09b (up 22% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공시 • Aug 24Givaudan SA to Report Q3, 2025 Results on Oct 14, 2025Givaudan SA announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 14, 2025공시 • Aug 23Givaudan SA to Report First Half, 2025 Results on Jul 22, 2025Givaudan SA announced that they will report first half, 2025 results on Jul 22, 2025Reported Earnings • Jul 24First half 2024 earnings released: EPS: CHF63.76 (vs CHF48.69 in 1H 2023)First half 2024 results: EPS: CHF63.76 (up from CHF48.69 in 1H 2023). Revenue: CHF3.74b (up 5.7% from 1H 2023). Net income: CHF588.0m (up 31% from 1H 2023). Profit margin: 16% (up from 13% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공시 • Jul 02Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a.Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a. on July 1, 2024. Givaudan plans to finance this acquisition through debt.Givaudan SA (SWX:GIVN) completed the acquisition of remaining 75% stake in B. Kolormakeup & Skincare S.p.a.Buy Or Sell Opportunity • Jul 01Now 16% overvalued after recent price riseOver the last 90 days, the stock has risen 7.1% to CHF4,302. The fair value is estimated to be CHF3,712, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.Buy Or Sell Opportunity • Jun 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.7% to CHF4,322. The fair value is estimated to be CHF3,564, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.공시 • Apr 12Givaudan SA to Report Fiscal Year 2024 Results on Jan 24, 2025Givaudan SA announced that they will report fiscal year 2024 results on Jan 24, 2025Upcoming Dividend • Mar 18Upcoming dividend of CHF68.00 per shareEligible shareholders must have bought the stock before 25 March 2024. Payment date: 27 March 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (3.0%).공시 • Feb 08Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) .Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) on February 6, 2024. The acquisition will be 100% funded by the External Growth Credit Line contracted by Groupe Berkem. The transaction is expected to be closed on May 31, 2024. Oghma Partners acted as exclusive corporate finance advisor to Givaudan S.A.Declared Dividend • Jan 28Dividend increased to CHF68.00Dividend of CHF68.00 is 1.5% higher than last year. Ex-date: 25th March 2024 Payment date: 27th March 2024 Dividend yield will be 1.9%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 6.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 23% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jan 26Full year 2023 earnings released: EPS: CHF96.81 (vs CHF92.83 in FY 2022)Full year 2023 results: EPS: CHF96.81 (up from CHF92.83 in FY 2022). Revenue: CHF6.92b (down 2.8% from FY 2022). Net income: CHF893.0m (up 4.3% from FY 2022). Profit margin: 13% (in line with FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공시 • Oct 19Givaudan SA to Report First Half, 2024 Results on Jul 23, 2024Givaudan SA announced that they will report first half, 2024 results on Jul 23, 2024공시 • Oct 17Givaudan SA, Annual General Meeting, Mar 21, 2024Givaudan SA, Annual General Meeting, Mar 21, 2024.Reported Earnings • Jul 21First half 2023 earnings released: EPS: CHF48.69 (vs CHF47.74 in 1H 2022)First half 2023 results: EPS: CHF48.69 (up from CHF47.74 in 1H 2022). Revenue: CHF3.54b (down 3.2% from 1H 2022). Net income: CHF449.0m (up 2.0% from 1H 2022). Profit margin: 13% (in line with 1H 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).Reported Earnings • Jan 26Full year 2022 earnings released: EPS: CHF92.83 (vs CHF89.03 in FY 2021)Full year 2022 results: EPS: CHF92.83 (up from CHF89.03 in FY 2021). Revenue: CHF7.12b (up 6.5% from FY 2021). Net income: CHF856.0m (up 4.3% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공시 • Jan 25Givaudan SA to Report Fiscal Year 2023 Results on Jan 25, 2024Givaudan SA announced that they will report fiscal year 2023 results on Jan 25, 2024공시 • Oct 12Givaudan SA to Report Q2, 2022 Results on Jul 20, 2023Givaudan SA announced that they will report Q2, 2022 results at 7:00 AM, Central European Standard Time on Jul 20, 2023Reported Earnings • Jul 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CHF481.0m from profit in 1H 2021). Profit margin: (down from 14% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.8% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.공시 • Jul 22Givaudan SA to Report Fiscal Year 2022 Results on Jan 25, 2023Givaudan SA announced that they will report fiscal year 2022 results on Jan 25, 2023Upcoming Dividend • Mar 21Upcoming dividend of CHF66.00 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 74% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (4.6%). Lower than average of industry peers (2.6%).공시 • Feb 16Givaudan SA, Annual General Meeting, Mar 23, 2023Givaudan SA, Annual General Meeting, Mar 23, 2023.Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jul 24First half 2021 earnings released: EPS CHF52.19 (vs CHF44.81 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF3.37b (up 4.7% from 1H 2020). Net income: CHF481.0m (up 17% from 1H 2020). Profit margin: 14% (up from 13% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Mar 22Upcoming Dividend of CHF64.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 1.8% is below the top quartile of British dividend payers (4.4%), but is in line with industry peers (1.7%).Is New 90 Day High Low • Feb 23New 90-day low: CHF3,511The company is down 2.0% from its price of CHF3,585 on 25 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,220 per share.Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CHF2,995, the stock is trading at a trailing P/E ratio of 44.3x, down from the previous P/E ratio of 55.1x. This compares to an average P/E of 41x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 53%.Is New 90 Day High Low • Feb 05New 90-day low: CHF2,995The company is down 24% from its price of CHF3,930 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,872 per share.Analyst Estimate Surprise Post Earnings • Feb 03Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 3.6% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Analyst Estimate Surprise Post Earnings • Feb 02Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 4.3% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Analyst Estimate Surprise Post Earnings • Jan 31Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 5.8% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Jan 30Full year 2020 earnings released: EPS CHF80.59 (vs CHF76.17 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF6.32b (up 1.9% from FY 2019). Net income: CHF743.0m (up 5.8% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Dec 04New 90-day low: CHF3,551The company is down 7.0% from its price of CHF3,810 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,941 per share.Is New 90 Day High Low • Nov 11New 90-day low: CHF3,672The company is down 4.0% from its price of CHF3,813 on 13 August 2020. The British market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,050 per share.Is New 90 Day High Low • Oct 05New 90-day high: CHF4,078The company is up 15% from its price of CHF3,541 on 07 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,996 per share.매출 및 비용 세부 내역Givaudan가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이LSE:0QPS 매출, 비용 및 순이익 (CHF Millions)날짜매출순이익일반관리비연구개발비31 Dec 257,4721,0711,23655130 Sep 257,5061,0831,25155630 Jun 257,5391,0941,26656031 Mar 257,4761,0921,24456331 Dec 247,4121,0901,22256530 Sep 247,2651,0611,18455130 Jun 247,1171,0321,14653731 Mar 247,0169631,12652831 Dec 236,9158931,10551930 Sep 236,9588791,10651830 Jun 237,0008651,10651631 Mar 237,0598611,10951931 Dec 227,1178561,11252230 Sep 227,0408181,13053830 Jun 226,9637801,14855331 Mar 226,8248011,15755831 Dec 216,6848211,16556230 Sep 216,5798161,14555730 Jun 216,4748111,12455231 Mar 216,3987771,09854431 Dec 206,3227431,07253630 Sep 206,3267391,06353330 Jun 206,3307351,05453031 Mar 206,2677191,03852931 Dec 196,2037021,02152830 Sep 196,0756871,00052030 Jun 195,94767297851231 Mar 195,73766895649531 Dec 185,52766393447730 Sep 185,38568591446030 Jun 185,24270789444231 Mar 185,14771487743331 Dec 175,05172085942430 Sep 174,93269084941730 Jun 174,81266083940931 Mar 174,73865283940531 Dec 164,66364483940030 Sep 164,60564882939030 Jun 164,54665181938031 Mar 164,47163880637331 Dec 154,39662579336630 Sep 154,39761380037830 Jun 154,397600807390양질의 수익: 0QPS는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 0QPS의 현재 순 이익률 (14.3%)은 지난해 (14.7%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 0QPS의 수익은 지난 5년 동안 연평균 8.3% 증가했습니다.성장 가속화: 0QPS은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: 0QPS은 지난 1년 동안 수익이 감소(-1.7%)하여 Chemicals 업계 평균(-59.9%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: 0QPS의 자본 수익률(23.4%)은 높음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/23 20:35종가2026/06/23 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Givaudan SA는 36명의 분석가가 다루고 있습니다. 이 중 18명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Konstantin WiechertBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchJames KnightBarclays33명의 분석가 더 보기
공시 • Apr 15Givaudan SA to Report Fiscal Year 2026 Results on Jan 27, 2027Givaudan SA announced that they will report fiscal year 2026 results on Jan 27, 2027
Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF116 (vs CHF118 in FY 2024)Full year 2025 results: EPS: CHF116 (down from CHF118 in FY 2024). Revenue: CHF7.47b (flat on FY 2024). Net income: CHF1.07b (down 1.7% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
공시 • Nov 08Givaudan SA to Report First Half, 2026 Results on Jul 23, 2026Givaudan SA announced that they will report first half, 2026 results on Jul 23, 2026
Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF64.18 (vs CHF63.76 in 1H 2024)First half 2025 results: EPS: CHF64.18 (up from CHF63.76 in 1H 2024). Revenue: CHF3.86b (up 3.4% from 1H 2024). Net income: CHF592.0m (flat on 1H 2024). Profit margin: 15% (in line with 1H 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
공시 • Apr 10Givaudan SA to Report Fiscal Year 2025 Results on Jan 29, 2026Givaudan SA announced that they will report fiscal year 2025 results on Jan 29, 2026
Reported Earnings • Jan 25Full year 2024 earnings released: EPS: CHF118 (vs CHF96.81 in FY 2023)Full year 2024 results: EPS: CHF118 (up from CHF96.81 in FY 2023). Revenue: CHF7.41b (up 7.2% from FY 2023). Net income: CHF1.09b (up 22% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • May 22Givaudan SA, Annual General Meeting, Mar 24, 2027Givaudan SA, Annual General Meeting, Mar 24, 2027.
공시 • Apr 15Givaudan SA to Report Fiscal Year 2026 Results on Jan 27, 2027Givaudan SA announced that they will report fiscal year 2026 results on Jan 27, 2027
공시 • Apr 08Givaudan Active Beauty Showcases AI-Powered Ingredient Innovations With Haut.AI At In-Cosmetics GlobalGivaudan Active Beauty, the reference in high-precision beauty ingredients, has partnered with Haut.AI, to spotlight a new era of AI-driven ingredient innovation. At this year's in-cosmetics Global 2026 (April 14–16, Paris), Givaudan Active Beauty will be the first to showcase its latest active ingredients through immersive GenAI-powered activations that allow attendees to virtually "experience" their benefits firsthand via personalized, photorealistic simulations powered by Haut.AI's SkinGPT technology. As the beauty industry accelerates toward measurable efficacy, personalization, and clinically validated claims, artificial intelligence is becoming a critical bridge between laboratory science and visible consumer outcomes. In this spirit, Givaudan has selected Haut.AI's scientifically grounded skin analysis and SkinGPT simulation technologies to deliver an interactive, ingredient-focused experience at one of the industry's most influential global stages. Building on this collaboration, Givaudan Active Beauty's latest active ingredient will serve as the foundation for an interactive SkinGPT-powered virtual try-on experience at the Givaudan booth in Paris. By taking a selfie of their own face, attendees will be able to digitally "apply" the ingredient and visualize how it may influence visible skin parameters over time through a photorealistic simulation. Meanwhile they will be able to experience an AI Skin Expert analyzing their skin and delivering personalized recommendations of high precision beauty ingredients. Givaudan Active Beauty's latest breakthrough, PrimalHyal™ NeuroYouth targets the newly identified Neuro Skin Ageing pathway, supporting nerve fiber regeneration and neuronal function. By integrating AI-powered validation and immersive simulations at booth at in-cosmetics Global, the company will share this innovation in a way that allows both customers and consumers to truly experience it. Visitors to the Givaudan Active Beauty booth will be invited to engage with two AI-powered experiences: SkinGPT: At in-cosmetics Global 2026, Givaudan will unveil its latest active ingredient in an immersive experience. For the first time, attendees will be able to literally try on the formulation on their own skin through a live facial scan, instantly visualizing how it may transform visible skin parameters over time. AI Skin Expert: An on-site skin assessment providing participants with comprehensive skin insights and active ingredient recommendations aligned with their unique skin characteristics.
Upcoming Dividend • Mar 16Upcoming dividend of CHF72.00 per shareEligible shareholders must have bought the stock before 23 March 2026. Payment date: 25 March 2026. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (4.1%).
공시 • Feb 23Givaudan SA, Annual General Meeting, Mar 19, 2026Givaudan SA, Annual General Meeting, Mar 19, 2026, at 10:30 W. Europe Standard Time.
Declared Dividend • Feb 01Dividend increased to CHF72.00Dividend of CHF72.00 is 2.9% higher than last year. Ex-date: 23rd March 2026 Payment date: 25th March 2026 Dividend yield will be 2.4%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (55% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jan 30Full year 2025 earnings released: EPS: CHF116 (vs CHF118 in FY 2024)Full year 2025 results: EPS: CHF116 (down from CHF118 in FY 2024). Revenue: CHF7.47b (flat on FY 2024). Net income: CHF1.07b (down 1.7% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
공시 • Jan 30Givaudan SA announces Annual dividend, payable on March 25, 2026Givaudan SA announced Annual dividend of CHF 72.0000 per share payable on March 25, 2026, ex-date on March 23, 2026 and record date on March 24, 2026.
공시 • Nov 08Givaudan SA to Report First Half, 2026 Results on Jul 23, 2026Givaudan SA announced that they will report first half, 2026 results on Jul 23, 2026
공시 • Aug 28Givaudan SA Announces CEO ChangesGivaudan SA announced that Christian Stammkoetter would succeed its Chief Executive Officer, Gilles Andrier, who will retire after 20 years at the helm of the company. Stammkoetter-- who is currently president of Asia, Middle East and Africa at the French food company Danone--would take over the role effective March 1. Andrier will be proposed for election as chairman at the 2026 annual general meeting as Calvin Grieder is set to step down from the board after 12 years.
Reported Earnings • Jul 24First half 2025 earnings released: EPS: CHF64.18 (vs CHF63.76 in 1H 2024)First half 2025 results: EPS: CHF64.18 (up from CHF63.76 in 1H 2024). Revenue: CHF3.86b (up 3.4% from 1H 2024). Net income: CHF592.0m (flat on 1H 2024). Profit margin: 15% (in line with 1H 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
공시 • Apr 10Givaudan SA to Report Fiscal Year 2025 Results on Jan 29, 2026Givaudan SA announced that they will report fiscal year 2025 results on Jan 29, 2026
Upcoming Dividend • Mar 17Upcoming dividend of CHF70.00 per shareEligible shareholders must have bought the stock before 24 March 2025. Payment date: 26 March 2025. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (4.2%).
공시 • Feb 24Givaudan SA, Annual General Meeting, Mar 20, 2025Givaudan SA, Annual General Meeting, Mar 20, 2025, at 10:30 W. Europe Standard Time.
Declared Dividend • Feb 17Dividend increased to CHF70.00Dividend of CHF70.00 is 2.9% higher than last year. Ex-date: 24th March 2025 Payment date: 26th March 2025 Dividend yield will be 1.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jan 25Full year 2024 earnings released: EPS: CHF118 (vs CHF96.81 in FY 2023)Full year 2024 results: EPS: CHF118 (up from CHF96.81 in FY 2023). Revenue: CHF7.41b (up 7.2% from FY 2023). Net income: CHF1.09b (up 22% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • Aug 24Givaudan SA to Report Q3, 2025 Results on Oct 14, 2025Givaudan SA announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 14, 2025
공시 • Aug 23Givaudan SA to Report First Half, 2025 Results on Jul 22, 2025Givaudan SA announced that they will report first half, 2025 results on Jul 22, 2025
Reported Earnings • Jul 24First half 2024 earnings released: EPS: CHF63.76 (vs CHF48.69 in 1H 2023)First half 2024 results: EPS: CHF63.76 (up from CHF48.69 in 1H 2023). Revenue: CHF3.74b (up 5.7% from 1H 2023). Net income: CHF588.0m (up 31% from 1H 2023). Profit margin: 16% (up from 13% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공시 • Jul 02Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a.Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a. on July 1, 2024. Givaudan plans to finance this acquisition through debt.Givaudan SA (SWX:GIVN) completed the acquisition of remaining 75% stake in B. Kolormakeup & Skincare S.p.a.
Buy Or Sell Opportunity • Jul 01Now 16% overvalued after recent price riseOver the last 90 days, the stock has risen 7.1% to CHF4,302. The fair value is estimated to be CHF3,712, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.
Buy Or Sell Opportunity • Jun 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 6.7% to CHF4,322. The fair value is estimated to be CHF3,564, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period.
공시 • Apr 12Givaudan SA to Report Fiscal Year 2024 Results on Jan 24, 2025Givaudan SA announced that they will report fiscal year 2024 results on Jan 24, 2025
Upcoming Dividend • Mar 18Upcoming dividend of CHF68.00 per shareEligible shareholders must have bought the stock before 25 March 2024. Payment date: 27 March 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (3.0%).
공시 • Feb 08Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) .Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) on February 6, 2024. The acquisition will be 100% funded by the External Growth Credit Line contracted by Groupe Berkem. The transaction is expected to be closed on May 31, 2024. Oghma Partners acted as exclusive corporate finance advisor to Givaudan S.A.
Declared Dividend • Jan 28Dividend increased to CHF68.00Dividend of CHF68.00 is 1.5% higher than last year. Ex-date: 25th March 2024 Payment date: 27th March 2024 Dividend yield will be 1.9%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 6.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 23% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jan 26Full year 2023 earnings released: EPS: CHF96.81 (vs CHF92.83 in FY 2022)Full year 2023 results: EPS: CHF96.81 (up from CHF92.83 in FY 2022). Revenue: CHF6.92b (down 2.8% from FY 2022). Net income: CHF893.0m (up 4.3% from FY 2022). Profit margin: 13% (in line with FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공시 • Oct 19Givaudan SA to Report First Half, 2024 Results on Jul 23, 2024Givaudan SA announced that they will report first half, 2024 results on Jul 23, 2024
공시 • Oct 17Givaudan SA, Annual General Meeting, Mar 21, 2024Givaudan SA, Annual General Meeting, Mar 21, 2024.
Reported Earnings • Jul 21First half 2023 earnings released: EPS: CHF48.69 (vs CHF47.74 in 1H 2022)First half 2023 results: EPS: CHF48.69 (up from CHF47.74 in 1H 2022). Revenue: CHF3.54b (down 3.2% from 1H 2022). Net income: CHF449.0m (up 2.0% from 1H 2022). Profit margin: 13% (in line with 1H 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).
Upcoming Dividend • Mar 20Upcoming dividend of CHF67.00 per share at 2.3% yieldEligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%).
Reported Earnings • Jan 26Full year 2022 earnings released: EPS: CHF92.83 (vs CHF89.03 in FY 2021)Full year 2022 results: EPS: CHF92.83 (up from CHF89.03 in FY 2021). Revenue: CHF7.12b (up 6.5% from FY 2021). Net income: CHF856.0m (up 4.3% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공시 • Jan 25Givaudan SA to Report Fiscal Year 2023 Results on Jan 25, 2024Givaudan SA announced that they will report fiscal year 2023 results on Jan 25, 2024
공시 • Oct 12Givaudan SA to Report Q2, 2022 Results on Jul 20, 2023Givaudan SA announced that they will report Q2, 2022 results at 7:00 AM, Central European Standard Time on Jul 20, 2023
Reported Earnings • Jul 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CHF481.0m from profit in 1H 2021). Profit margin: (down from 14% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.8% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year.
공시 • Jul 22Givaudan SA to Report Fiscal Year 2022 Results on Jan 25, 2023Givaudan SA announced that they will report fiscal year 2022 results on Jan 25, 2023
Upcoming Dividend • Mar 21Upcoming dividend of CHF66.00 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 74% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (4.6%). Lower than average of industry peers (2.6%).
공시 • Feb 16Givaudan SA, Annual General Meeting, Mar 23, 2023Givaudan SA, Annual General Meeting, Mar 23, 2023.
Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jan 30Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jul 24First half 2021 earnings released: EPS CHF52.19 (vs CHF44.81 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF3.37b (up 4.7% from 1H 2020). Net income: CHF481.0m (up 17% from 1H 2020). Profit margin: 14% (up from 13% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Mar 22Upcoming Dividend of CHF64.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 1.8% is below the top quartile of British dividend payers (4.4%), but is in line with industry peers (1.7%).
Is New 90 Day High Low • Feb 23New 90-day low: CHF3,511The company is down 2.0% from its price of CHF3,585 on 25 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,220 per share.
Valuation Update With 7 Day Price Move • Feb 05Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to CHF2,995, the stock is trading at a trailing P/E ratio of 44.3x, down from the previous P/E ratio of 55.1x. This compares to an average P/E of 41x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 53%.
Is New 90 Day High Low • Feb 05New 90-day low: CHF2,995The company is down 24% from its price of CHF3,930 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,872 per share.
Analyst Estimate Surprise Post Earnings • Feb 03Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 3.6% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Analyst Estimate Surprise Post Earnings • Feb 02Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 4.3% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Analyst Estimate Surprise Post Earnings • Jan 31Revenue misses expectationsRevenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 5.8% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Jan 30Full year 2020 earnings released: EPS CHF80.59 (vs CHF76.17 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF6.32b (up 1.9% from FY 2019). Net income: CHF743.0m (up 5.8% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Dec 04New 90-day low: CHF3,551The company is down 7.0% from its price of CHF3,810 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,941 per share.
Is New 90 Day High Low • Nov 11New 90-day low: CHF3,672The company is down 4.0% from its price of CHF3,813 on 13 August 2020. The British market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,050 per share.
Is New 90 Day High Low • Oct 05New 90-day high: CHF4,078The company is up 15% from its price of CHF3,541 on 07 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,996 per share.